A Minimally Invasive Outpatient Technology for the treatment of Obstructive Sleep Apnea
Powered by Cleveland Clinic technology, Enhale Medical’s neuromodulation solution leverages scientific discovery and clinical expertise.Our Solution
Estimated total annual economic cost of moderate to severe OSA in the U.S.
This is greater than asthma, heart failure, stroke and hypertensive disease ($20-$80B).
Harvard Medical School Division of Sleep Medicine, The price of fatigue; The surprising economic costs of unmanaged sleep apnea, December 2010
Sutherland K, Phillips CL, Cistulli PA, Efficacy versus effectiveness in the treatment of obstructive sleep apnea. CPAP and oral appliances. Journal of Dental Sleep Medicine 2015, 2(4) 175-181
of all patients diagnosed with sleep apnea and prescribed CPAP therapy will abandon treatment or fail on CPAP.
People with untreated sleep apnea face more than 3x the risk of premature death and more than 5x the risk of cardiovascular mortality.
Young, T., Finn, L., Peppard, P.E., et al. Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort. Sleep. Sleep Research Society. 2008 Aug 1; 31(8): 1071–1078.
Our next-generation technology is patient-centered to proactively treat obstructive sleep apnea.
Rooted in Science
Focused on the development of therapy derived from research into the origins of obstructive sleep apnea.
Our technology leverages clinical research and technical expertise of the Cleveland Clinic.
Enhale Medical is comprised of a team of some of the best minds in the medical industry. Our team represents a wide range of knowledge across disciplines crucial to a successful venture in today’s ever-changing market.
Josh Nickols, PhD
Frank Papay, MD